行情

AERI

AERI

Aerie制药
NASDAQ

实时行情|Nasdaq Last Sale

13.05
-0.45
-3.33%
盘后: 13.05 0 0.00% 16:00 03/27 EDT
开盘
13.08
昨收
13.50
最高
13.68
最低
12.70
成交量
82.72万
成交额
--
52周最高
49.16
52周最低
10.80
市值
6.06亿
市盈率(TTM)
-2.9707
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AERI价格均价为37.17,最高价位54.00,最低价为17.00。

EPS

AERI 新闻

更多
  • Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap
  • TipRanks · 4天前
  • Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
  • Zacks · 03/21 16:30
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

AERI 简况

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
展开

微牛提供Aerie Pharmaceuticals Inc(NASDAQ-AERI)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AERI股票新闻,以帮助您做出投资决策。